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Abstract
Tumor necrosis factor-alpha (TNF-α) is one of the most important
proinflammatory cytokines which plays a central role in host defense
and in the acute inflammatory response related to tissue injury. The
major source of TNF-α are immune cells such as neutrophils and
macrophages. We tested the hypothesis that pentoxifylline, a methyl-
xanthine derivative, down-regulates proinflammatory cytokine ex-
pression during acute lung injury in rats. Male Wistar rats weighing
250 to 450 g were anesthetized ip with 50 mg/kg sodium thiopental
and randomly divided into three groups: group 1 (N = 7): tidal volume
(VT) = 7 ml/kg, respiratory rate (RR) = 50 breaths/min and normal
saline infusion; group 2 (N = 7): VT = 42 ml/kg, RR = 9 breaths/min
and normal saline infusion; group 3 (N = 7): VT = 42 ml/kg, RR = 9
breaths/min and pentoxifylline infusion. The animals were ventilated
with an inspired oxygen fraction of 1.0, a positive end-expiratory
pressure of 3 cmH2O, and normal saline or pentoxifylline injected into
the left femoral vein. The mRNA of TNF-α rapidly increased in the
lung tissue within 180 min of ventilation with a higher VT with normal
saline infusion. The concentrations of inflammatory mediators were
decreased in plasma and bronchoalveolar lavage (BAL) in the pres-
ence of higher VT with pentoxifylline infusion (TNF-α: plasma, 102.2
± 90.9 and BAL, 118.2 ± 82.1; IL-1ß: plasma, 45.2 ± 42.7 and BAL,
50.2 ± 34.9, P < 0.05). We conclude that TNF-α produced by neutro-
phil influx may function as an alert signal in host defense to induce
production of other inflammatory mediators.
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Introduction
In clinical disorders such as acute respi-
ratory distress syndrome (ARDS), asthma,
sepsis and shock, regardless of the underly-
ing insults, the host initiates an inflammatory
response with the release of numerous me-
diators, in particular, proinflammatory cyto-
kines which may potentiate organ injury.
However, depending on the ventilatory strat-
egy, mechanical ventilation itself can either
perpetuate or worsen previous lung injury.
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Various experimental studies have demon-
strated that mechanical ventilation with high
tidal volumes (VT) and/or high transpulmo-
nary pressures causes lung injury (1-4). Stud-
ies on lung lavage have shown increased
levels of tumor necrosis factor-alpha (TNF-
α), interleukins (IL)-1ß, -6 and -10, inter-
feron-γ and thromboxane ß2, suggesting an
ongoing pulmonary inflammatory response
(4-6) that is often associated with the migra-
tion of neutrophils to the lung (7).
Pentoxifylline (PTX), a phosphodiester-
ase inhibitor, has hemorheologic activity
thought to be based on its ability to reduce
blood viscosity, decreases serum levels of
TNF-α, increases the filtrability of blood
cells and it is widely used for treatment of
immune function. This drug has been shown
to attenuate the symptoms of endotoxin shock
and ARDS and is used clinically in the man-
agement of vascular diseases, especially mi-
crocirculatory dysfunction (8). In addition to
acting as an anti-inflammatory agent, it can
also suppress the synthesis of TNF-α by
monocytes and lung macrophages (9-16).
Studies using PTX have demonstrated leu-
kocyte inhibition (17), and a decreased pro-
duction of superoxide anions and release of
granular enzymes from neutrophils (18-20).
Experimental studies on endotoxemia in ani-
mals have shown that pretreatment with PTX
improves the survival rate. In ARDS-simu-
lating experimental studies, pretreatment with
PTX or its administration after induction of
the pathological state results in inhibited
protein extravasation and sequestration of
neutrophils (21-23).
Due to these anti-inflammatory proper-
ties and supported by experimental studies,
PTX was used for the treatment of patients
with ARDS, a condition in which inflamma-
tory mediators and neutrophils are known to
play an important role in the genesis of lung
injury (24). However, the results have been
disappointing (25), indicating that a better
understanding of both the mechanisms un-
derlying ventilator-induced lung injury (VILI)
and the effect of PTX on this condition is
required.
We tested the hypothesis that treatment
with PTX can attenuate VILI by reducing the
production of inflammatory cytokines and
thus acute lung injury. We used a rat model
of VILI and observed that PTX administra-
tion reduced lung edema, histological endo-
thelial injury, lung neutrophil migration and
cytokine response under high VT ventilation,
suggesting that PTX may be useful for the
treatment of VILI.
Material and Methods
Animal preparation
The study was approved by the Institu-
tional Research Ethics Committee of the
Federal University of São Paulo (UNIFESP/
EPM; #014/00), São Paulo, SP, Brazil. All
animals received humane care in compli-
ance with the “Principles of Laboratory Ani-
mal Care” formulated by the National Socie-
ty for Medical Research (USA), the “Guide
for the Care and Use of Laboratory Animals”
prepared by the Institute of Laboratory Ani-
mal Resources, published by the National
Institutes of Health (USA), and with the
“Guidance on the Operation of the Animals
(Scientific Procedures) Act 1986” published
by Her Majesty’s Stationery Office, London,
England.
Male Wistar rats weighing 250 to 450 g
were anesthetized ip with 50 mg/kg sodium
thiopental (Thionembutal, Abbott, São Paulo,
SP, Brazil). Muscle relaxation was main-
tained with 0.8 mg/kg pancuronium bro-
mide, ip (Pavulon, Organon, São Paulo, SP,
Brazil). The animals received either a high
dose (50 mg/kg) of PTX (Trental®, Hoechst
Marion Roussel, São Paulo, SP, Brazil) or
normal saline at 100 mg/kg (in bolus) in-
jected into the caudal vein. A continuous
PTX or normal saline infusion (50 mg kg-1
h-1) with a syringe pump model ‘11’ (Single
Syringe 55-1111, Harvard Apparatus,
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Holliston, MA, USA) was administered af-
ter surgical preparation as described below.
Surgical preparation. Tracheostomy was
performed and a 14-G cannula was inserted
into the trachea. The sterile catheter, PE-50
tubing (Intramedic Polyethylene Tubing,
Becton Dickinson, Jersey City, NJ, USA),
was inserted into the left internal carotid
artery for the determination of blood gases
(PaO2 and PaCO2) and pH (ABL-330, Radi-
ometer, Copenhagen, Denmark), and the left
femoral vein was cannulated for PTX or
normal saline infusion.
Experimental protocol and measurements
The rats were divided into three groups,
one receiving PTX and two receiving normal
saline. Group 1 (G1): the rats (N = 7) were
ventilated with a low volume ventilation (VT =
7 ml/kg, positive end-respiratory pressure
(PEEP) = 3 cmH2O, respiratory rate (RR) =
50 breaths/min, inspiratory flow = 20 ml/s)
with normal saline infusion for 180 min;
group 2 (G2): the rats (N = 7) were ventilated
with a high volume ventilation (VT = 42 ml/
kg, PEEP = 3 cmH2O, RR = 9 breaths/min,
inspiratory flow = 20 ml/s) with normal sa-
line infusion for 180 min; group 3 (G3): the
rats (N = 7) were ventilated with a high
volume ventilation (VT = 42 ml/kg, PEEP =
3 cmH2O, RR = 9 breaths/min, inspiratory
flow = 20 ml/s) with PTX infusion for 180
min.
Initial mechanical ventilation. During the
first period the rats were initially ventilated
for 20 min with a VT of 7 ml/kg and an RR of
50 breaths/min, PEEP of 3 cmH2O, inspira-
tory flow of 20 ml/s and an inspired oxygen
fraction of 1.0, in a time-cycled ventilator
(Intermed, São Paulo, SP, Brazil) adapted
for small animals. At the end of this ventila-
tory period, arterial blood gases were regu-
lated to target an arterial oxygen pressure
(PaO2) ≥400 mmHg before the experiment
was started. Airway pressure was measured
with an MP 45 pressure transducer (Validyne
Engineering Corp., Nortbridge, CA, USA),
connected to the tracheostomy cannula, and
the signal was recorded continuously on a
strip chart recorder. VT was estimated with a
small type pneumotachograph (Pneumotach,
Hans Rudolf Inc., Kansas City, KS, USA)
connected to an MP 45 ± 2 cmH2O trans-
ducer.
Arterial blood gases. PaO2 and PaCO2
and pH were measured with an automatic
analyzer at 20, 30, 90 and 180 min after the
initiation of mechanical ventilation.
Pressure-volume curve. At the end of the
experiment (post-ventilation) the abdomen
was opened and a blood sample was ob-
tained from the inferior vena cava. The ani-
mal was sacrificed, and a pressure-volume
curve was determined (N = 7/group) as pre-
viously described (26) by inflating/deflating
the lungs with 0.5- to 1-ml aliquots of atmo-
spheric air (with a water column) to a maxi-
mal transpulmonary pressure of 30 cmH2O.
Bronchoalveolar lavage (BAL). The right
lung was washed three times with 30 ml/kg
normal saline (0.9% NaCl) at 4ºC. The cell
pellets were resuspended and a 1-ml aliquot
was separated for cell counting. The cell
pellets were centrifuged at 1,500 g for 10
min at 4ºC using a model 5415R Eppendorf
centrifuge (Hamburg, Germany) and the su-
pernatant was stored at -80ºC for further
measurements.
Protein leakage. Protein concentration
was determined spectrophotometrically in
duplicate by the method of Lowry et al. (27)
in the aliquots of the BAL.
Cell differentiation. The total cell num-
ber in BAL fluid was counted with a hemocy-
tometer (Neubauer chamber). The pellet was
spun in a LABHO, model CT 120 centrifuge
(São Paulo, SP, Brazil) at 530 g for 10 min.
A differential cell count of 200 cells was
obtained by light microscopy (Carl Zeiss,
Axiolab, Jena, Germany) with a digital color
camera (Hyper HAD, Sony Inc., New York,
NY, USA).
Cytokine assay. Cytokine concentrations
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in plasma and BAL were measured with
specific commercially available enzyme-
linked immunosorbent assay (ELISA) kits
according to manufacturer instructions. The
kit for TNF-α (Factor-test-x/RAT TNF-α)
was from Genzyme (Cambridge, MA, USA)
and the kit for IL-1ß was from R&D Systems
(Minneapolis, MN, USA). The sensitivity of
the kits for TNF-α and IL-1ß was 10 and 5
pg/ml, respectively.
Tissue preparation for the reverse trans-
cription-polymerase chain reaction (RT-
PCR). A lung homogenate was obtained from
each group (G1, G2 and G3). mRNA for
TNF-α expression and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH, house-
keeping gene) was determined semiquanti-
tatively by RT-PCR. Cytoplasmic RNA was
extracted from rat lung using the Trizol total
RNA isolation kit (Gibco-BRL, Gaithersburg,
MD, USA). The amount of RNA was quan-
tified by absorbance at 260 nm. Sample qual-
ity was checked by running the RNA on
1.5% agarose gels.
Total RNA (1 µg) from each sample was
reverse transcribed into cDNA using oligo
(dT) as a primer. PCR conditions were 32
cycles of denaturation at 94ºC for 40 s and
annealing at 55ºC for 30 s using a GeneAmp
PCR System 9700 thermocycler (Perkin
Elmer, Norwalk, CT, USA). The primers for
TNF-α [AF269159] were: sense, 5'-TCA
GCC TCT TCT CAT TCC TGC-3'/antisense,
5'-GTG CAG CAT CGT TTG GTG GTT-3'
and the primers for GAPDH were: sense, 5'-
GTG AAG GTC GGT GTG AAC GGA
TTT-3'/antisense, 5'-CAC AGT CTT CTG
AGT GGC AGT GAT-3'. The GAPDH sig-
nals were used to control for variation in the
efficiency of RNA extraction, reverse trans-
cription, and PCR.
The PCR products were separated by
electrophoresis on 2% agarose gel contain-
ing 0.2 µl/ml ethidium bromide. The PCR
products were visualized with an M26 trans-
illuminator (BioAgency, São Paulo, SP, Bra-
zil) at 302 nm, the membrane was scanned,
the resulting images were captured, and the
results were analyzed with Kodak Digital
Science EDAS 120 software (Eastman Kodak
Company, Rochester, NY, USA). The rela-
tive expression of TNF-α mRNA was calcu-
lated as the ratio of the densities of the TNF-α
and GAPDH bands.
Statistical analysis
Data are reported as means ± SD and
were collected and analyzed using the SPSS
statistical software (SPSS 10.0, SPSS Sci-
ence, Chicago, IL, USA). Data were also
analyzed by one-way ANOVA followed by
the Tukey-Kramer test. Repeated measures
analysis of variance was used for PaO2,
PaCO2 and pH. A P value <0.05 or 5% was
considered statistically significant.
Results
All animals survived the protocol. The
pressure-volume curves obtained with 10
and 20 cmH2O were lower in the G2 group
than in the G1 group. PTX pretreatment (G3)
resulted in pressure-volume curves higher
than normal saline (G2) for the same ventila-
tion volume (VT = 42 ml/kg) (Table 1). In-
creased VT induced a striking leakage of
proteins (G1 vs G2), a finding partially re-
versed by PTX treatment (Table 1).
BAL cellularity (cells/mm3) was signifi-
cantly higher (P < 0.0001) in the G2 group
compared with the G1 and G3 groups. The
G2 group showed a lower percentage of
macrophages and a higher percentage of neu-
trophils compared to the G1 and G3 groups
(Table 1).
During the first 20-min period of me-
chanical ventilation all variables regarding
arterial blood gases were similar among the
groups. PaO2 decreased in animals with
higher VT (42 ml/kg, G2) after 90 and 180
min of mechanical ventilation, a dysfunction
prevented by PTX treatment (G3) (Table 2).
No differences in PaCO2 or pH were found
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among the groups during the 20- and 30-min
period of mechanical ventilation, but pH
decreased in animals with higher VT in the
G2 and G3 groups compared to the G1 group
(Table 2).
TNF-α levels measured in plasma and
BAL (Figure 1A and B) were higher in ani-
mals ventilated with a higher volume (G2:
plasma, 1987.5 ± 100.2 and BAL, 1144.6 ±
272.7 pg/ml) than in those ventilated with a
low volumes (G1: plasma, 177.2 ± 21.1 and
BAL, 225.8 ± 28.1 pg/ml). PTX treatment
(G3: plasma, 102.2 ± 90.9 and BAL, 118.2 ±
82.1 pg/ml) prevented the release of TNF-α
induced by a higher ventilatory volume in
both plasma and BAL (Figure 1A and B).
Table 1. Effect of pentoxifylline on total cell count, macrophages, neutrophils and total protein in bronchoalveo-
lar lavage, wet-to-dry ratio (W:D), and transpulmonary pressure (Tp) in 10 and 20 cmH2O.
G1 G2 G3
Total cells (cells/mm3) 81.42 ± 18.17 159.14 ± 42.25 113.14 ± 11.71
Macrophages (%) 65.00 ± 5.5 24.7 ± 9.7 57.5 ± 9.9
Neutrophils (%) 15.7 ± 6.4 60.7 ± 10.0 26.3 ± 6.0
Total protein (mg) 9.38 ± 0.90 52.67 ± 9.32 25.69 ± 2.24
W:D (g) 8.77 ± 1.22 10.58 ± 1.34 8.29 ± 1.53
Tp (10 cmH2O) 5.57 ± 1.90 4.86 ± 1.12 7.71 ± 1.38
Tp (20 cmH2O) 13.00 ± 2.45 11.71 ± 2.21 15.57 ± 1.81
Data are reported as mean ± SD for 7 animals in each group. Infusion rate of pentoxifylline and normal saline:
50 mg kg-1 h-1.
Total cell count = G1 vs G2 (P < 0.001) and G2 vs G3 (P < 0.05).
Macrophages = G1 vs G2 (P < 0.001) and G2 vs G3 (P < 0.001).
Neutrophils = G1 vs G2 (P < 0.001) and G2 vs G3 (P < 0.001).
Total protein = G1 vs G2 (P < 0.001), G1 vs G3 (P < 0.001) and G2 vs G3 (P < 0.001).
W:D = G2 vs G3 (P < 0.0143).
Tp (10 cmH2O) = G1 vs G2 (P > 0.05), G1 vs G3 (P < 0.05) and G2 vs G3 (P < 0.01).
Tp (20 cmH2O) = G1 vs G2 (P > 0.05), G1 vs G3 (P > 0.05) and G2 vs G3 (P < 0.05) (ANOVA).
Table 2. Arterial blood gases of rats during mechanical ventilation in the presence and absence of pentoxifylline.
20 min 30 min 90 min 180 min
G1 G2 G3 G1 G2 G3 G1 G2 G3 G1 G2 G3
PaO2 (mmHg)
517.1 517.1 505.6 512.0 572.8 569.5 517.9 408.5 587.0 542.8 190.5 615.8
±44.1 ±53.6 ±44.6 ±49.8 ±37.5 ±41.6 ±59.1 ± 81.1 ±38.3 ±38.2 ±65.4 ±26.0
PaCO2 (mmHg)
41.8 46.1 41.9 43.2 46.6 44.3 44.5 40.5 38.8 43.2 41.7 42.3
±4.8 ±9.6 ±8.7 ±6.8 ±7.59 ±7.44 ±10.5 ±9.5 ±10.8 ±4.7 ±12.3 ±10.8
pH
7.4 7.4 7.3 7.4 7.4 7.3 7.5 7.4 7.3 7.3 7.3 7.2
±0.09 ±0.04 ±0.09 ±0.05 ±0.05 ±0.08 ±0.13 ±0.07 ±0.07 ±0.05 ±0.08 ±0.05
PTX (50 mg/kg) was administered iv. The arterial blood gases are reported as means ± SD for 7 animals in
each group.
PaO2 (10 min) - G1 vs G2 (P < 0.05). PaO2 (90 min) - G1 vs G2 (P < 0.05), and G2 vs G3 (P < 0.001). PaO2 (180
min) - G1 vs G2 (P < 0.001), G1 vs G3 (P < 0.05), and G2 vs G3 (P < 0.001).
pH (90 min) - G1 vs G3 (P < 0.05). pH (180 min) - G1 vs G3 (P < 0.05), and G2 vs G3 (P < 0.05) (repeated
measures ANOVA).
PaCO2 did not differ significantly between groups.
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Similar results were obtained for IL-1ß lev-
els measured in plasma and BAL in G1
(plasma: 44 ± 32.2 and BAL: 48.6 ± 11.8 pg/
ml), G2 (plasma: 802.9 ± 164.4 and BAL:
914.7 ± 63.6 pg/ml), and G3 (plasma: 45.2 ±
42.7 and BAL: 50.2 ± 34.9 pg/ml) (Figure
2A and B).
To examine whether TNF-α synthesis is
effectively regulated at the transcriptional
level in tissue cells, total extracted RNA and
TNF-α mRNA levels were determined by
semiquantitative RT-PCR. The mRNA level
of TNF-α was low before PTX treatment. As
an internal control, there was no change in
mRNA level of GAPDH (Figure 3).
Discussion
Increased epithelial and endothelial per-
meability and development of pulmonary
edema (7,28) in association with the inflam-
matory response (6,7,29,30) have been dem-
onstrated in animals ventilated with high VT
and/or high transpulmonary pressure (7,28)
and were also observed in the present study.
The rats ventilated with high VT presented
increased protein leakage in addition to se-
vere hypoxemia, as well as a higher number
of cells in the BAL, mainly composed of
polymorphonuclear neutrophils. The fact that
these alterations were attenuated by the ad-
ministration of PTX clearly demonstrates
that this drug exerts a protective effect in this
Figure 2. Effect of pentoxifylline
(PTX) on IL-1ß levels in plasma
(A) and bronchoalveolar lavage
(B) of rats under mechanical ven-
tilation. Data are reported as
means ± SD. G1 (VT = 7 ml/kg
with normal saline infusion; N =
7); G2 (VT = 42 ml/kg with nor-
mal saline infusion; N = 7), and
G3 (VT = 42 ml/kg with PTX infu-
sion (50 mg/kg); N = 7). A, *P <
0.001 for G2 vs G1 vs G3. B, *P
< 0.001 for G2 vs G1 vs G3
(ANOVA).
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Figure 3. Effect of tidal volumes
on TNF-α mRNA expression in
lungs of rats subjected to me-
chanical ventilation. G1 (VT = 7
ml/kg with normal saline infu-
sion; N = 7); G2 (VT = 42 ml/kg
with normal saline infusion; N =
7), and G3 (VT = 42 ml/kg with
PTX infusion (50 mg/kg); N = 7).
Cellular RNA of lung tissue was
harvested 180 min after mechan-
ical ventilation and subjected to
semiquantitative RT-PCR. A,
TNF-α; B, control glyceraldehyde-
3-phosphate dehydrogenase
(GAPDH); C, densitometric analy-
sis of A + B.
Figure 1. Effect of pentoxifylline
(PTX) on TNF-α levels in plasma
(A) and bronchoalveolar lavage
(B) of rats under mechanical ven-
tilation. Data are reported as
means ± SD. G1 (VT = 7 ml/kg
with normal saline infusion; N =
7); G2 (VT = 42 ml/kg with nor-
mal saline infusion; N = 7), and
G3 (VT = 42 ml/kg with PTX infu-
sion (50 mg/kg); N = 7). A, *P <
0.001 for G2 vs G1 vs G3. B, *P
< 0.001 for G2 vs G1 vs G3
(ANOVA).
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experimental model of ARDS. The mechan-
ism of action of PTX is complex and incom-
pletely understood.
Blood arterial gases obtained during me-
chanical ventilation showed that high VT
had a profound impact on PaO2 after 180
min of mechanical ventilation (G1 vs G2).
This effect was completely reversed in ani-
mals treated with PTX (G3), in agreement
with other studies (23). Similarly, high VT
rats presented an impressive enhancement
of total protein in BAL, which was partially
reversed by PTX treatment. Increased pro-
tein leakage and wet-to-dry weight ratios
(Table 1) in these animals could be due to
direct physical damage to the barrier or be
secondary to enhanced endothelial perme-
ability (31).
Mandell’s (24) review of the anti-inflam-
matory effects of PTX highlights the major
actions of this drug on neutrophil function.
PTX reduces the production of inflamma-
tory cytokines by stimulated neutrophils and
blocks the effect of these cytokines on the
other phagocytes. Therefore, PTX decreases
the adherence, rigidity, oxidative burst, de-
granulation, and chemotactic movement of
neutrophils. Our study demonstrated that the
total cell number in BAL fluid was higher in
the G2 group (P < 0.0002) than in the other
groups (Table 1). There was an increased
number of neutrophils in the G2 group (P <
0.0001) and the number of macrophages in
the BAL was lower in the G2 group and
higher in the G3 group (Table 1). Thus, we
have found that PTX interferes with the ad-
hesion and extravasation of leukocytes in-
duced by mechanical ventilation. However,
the precise mechanisms underlying such ef-
fect are not clear.
The protective effect of PTX observed in
our study is supported by previous reports on
rats and rabbits. Seear et al. (23) demon-
strated in a rabbit lavage model that pretreat-
ment with 20.0 mg/kg PTX (bolus) followed
by continuous infusion of 20.0 mg kg-1 h-1
reduced lung edema. The cited study indi-
cates that PTX reduces edema formation in
rabbits after saline lavage, not by lowering
microvascular pressure for fluid filtration or
by accelerating alveolar fluid reabsorption,
but possibly by its anti-inflammatory effect
on neutrophil function.
Previous in vivo studies have shown that
PTX can decrease lung capillary permeabil-
ity (8,17). Thus, the present data, taken to-
gether with those from previous studies, sug-
gest that PTX attenuates lung injury (12,23,
32,33).
Inhibition of chemokine production and
intercellular adhesion molecule-1 expression
by IL-1, TNF-α and TNF-ß, cytokines with
different signal transduction pathways, is
likely to occur at the transcriptional level
also. However, other post-transcriptional
mechanisms might also be involved since
PTX blocked the production of chemokines
even 2-4 h after proinflammatory cytokine
addition. Studies are underway to elucidate
the mechanism of action of PTX. TNF-α is
believed to play an important role in the
inflammatory cascade (34). Studies on ani-
mals have demonstrated that overdistension
of the lungs by mechanical ventilation can
cause elevations in inflammatory cytokines
(35,36). Nash et al. (37) examined the distri-
bution of TNF-α in lung tissue from patients
dying of ARDS.
The participation of inflammatory cyto-
kines in the course of VILI has been the
subject of recent studies. Tremblay et al. (6)
examined the effects of different ventilatory
strategies on the concentrations of several
cytokines in BAL fluid from isolated rat
lungs ventilated with different end-expira-
tory pressures and VT. The high VT (40 ml/
kg) with zero-PEEP resulted in considerable
increases in TNF-α, IL-1ß, and IL-6 and in
macrophage inflammatory protein-2, a
chemokine of the IL-8 family. We have pre-
viously shown that mechanical ventilation
induces TNF-α secretion, detected in BAL
and serum, with higher levels found in ani-
mals ventilated with higher VT (38). We
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confirmed and expanded these results by
showing that high VT increases TNF-α
mRNA levels and the number of cytokines
(TNF-α and IL-1ß) in the plasma and BAL
of animals with VILI.
Numerous studies have shown that an
increase of intracellular cAMP is caused by
phosphodiesterase inhibition by PTX (39).
However, there is no consistent correlation
between increased blood mononuclear cells
(39) and other possible mechanisms as re-
vealed in a recent study showing that PTX
can inactivate ß1 integrins on T cells and
inhibit the expression of activation markers
CD25, CD69, and CD98 on T lymphocytes
stimulated with mitogens (40).
Nevertheless, it is possible that PTX ex-
erts its protective effect by inhibiting the
production and secretion of inflammatory
cytokines (24). In fact, we found a dramatic
reduction in plasma and BAL levels of TNF-
α and IL-1ß in animals treated with PTX,
suggesting that the inhibition of these in-
flammatory mediators may be responsible
for the protection mediated by PTX in VILI.
The mechanism responsible for the inhibi-
tion of TNF production by PTX may involve
alteration of the intracellular signaling path-
ways responsible for gene transcription, since
we found decreased TNF-α mRNA expres-
sion in tissues of PTX-treated animals com-
pared to the controls. Another very interest-
ing question regarding our findings is why
the increase in mRNA levels was lower than
the increase observed in plasma and BAL.
We believe that very likely the production of
cytokines might be controlled in a post-tran-
scriptional way so that cytokines are some-
how stored inside cells and therefore do not
need a very fast and strong gene transcrip-
tion activity.
The results of the present study have
important clinical and research implications
in that they emphasize the importance of
cellular uptake of a cytokine for the modula-
tion of the inflammatory cell response. Fur-
ther studies are needed to elucidate the ef-
fectiveness of these agents based on their in
vivo bioavailability, which will vary based
on route of administration and potential tox-
icity. Understanding the extent to which
changes in the redox state of inflammatory
cells alter their responses will have impor-
tant implications for the development of
therapeutic strategies to modulate the sys-
temic inflammatory response.
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